Cargando…

Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment

With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ling, Ning, Qian, Tang, Sheng-song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956433/
https://www.ncbi.nlm.nih.gov/pubmed/35340585
http://dx.doi.org/10.1155/2022/8052212
_version_ 1784676568585469952
author Yang, Ling
Ning, Qian
Tang, Sheng-song
author_facet Yang, Ling
Ning, Qian
Tang, Sheng-song
author_sort Yang, Ling
collection PubMed
description With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy.
format Online
Article
Text
id pubmed-8956433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89564332022-03-26 Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment Yang, Ling Ning, Qian Tang, Sheng-song J Immunol Res Review Article With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy. Hindawi 2022-03-18 /pmc/articles/PMC8956433/ /pubmed/35340585 http://dx.doi.org/10.1155/2022/8052212 Text en Copyright © 2022 Ling Yang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Yang, Ling
Ning, Qian
Tang, Sheng-song
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
title Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
title_full Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
title_fullStr Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
title_full_unstemmed Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
title_short Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
title_sort recent advances and next breakthrough in immunotherapy for cancer treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956433/
https://www.ncbi.nlm.nih.gov/pubmed/35340585
http://dx.doi.org/10.1155/2022/8052212
work_keys_str_mv AT yangling recentadvancesandnextbreakthroughinimmunotherapyforcancertreatment
AT ningqian recentadvancesandnextbreakthroughinimmunotherapyforcancertreatment
AT tangshengsong recentadvancesandnextbreakthroughinimmunotherapyforcancertreatment